CLASRP

Across TCGA pan-cancer cohorts, CLASRP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLASRP data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLASRP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CLASRP expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where CLASRP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.437	0.696	.006	23	view →
HNSC	OS	Median	All	0.380	1.000	.008	22	view →
LSCC	OS	Quartile	II,III,IV	0.933	0.501	.013	10	view →
UCEC	DFS	Median	II,III,IV	0.489	0.879	.010	6	view →
CCRCC	OS	Median	All	0.742	1.000	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLASRP–PDAC (OS)

Open the PDAC breakdown →